Coregulated metabolite networks associated with global protein crotonylation are central

pathophysiological processes in prediabetes and diabetes

Authors: Dhruv Dubey[1,2], Tumpa Dutta[2#], Anna Casu[2], Anton Iliuk,[3] Stephen J. Gardell[2],

Richard E. Pratley[1,2*], Yury O. Nunez Lopez[2*]

Affiliations: [1] Johns Hopkins University, Baltimore, ML 21218, USA; [2] AdventHealth

Translational Research Institute (TRI), Orlando, FL 32804, USA; [3] Tymora Analytical

Operations, West Lafayette, Indiana 47906, USA

[#] **Current address:** Brigham and Women's Hospital/Harvard Medical School, Boston, MA

02115, USA

*Correspondence: Yury.NunezLopez@AdventHealth.com &

Richard.Pratley.MD@AdventHealth.com

Abstract

Type 2 diabetes and prediabetes affect hundreds of millions of people globally, yet the metabolic

networks underlying disease development remain poorly understood. Using untargeted liquid

chromatography-mass spectrometry (LC-MS/MS), we profiled a total of 15,470 (900 known)

serum metabolite features across the human diabetes spectrum (the most comprehensive

coverage reported to date). Weighted coexpression network analysis of samples from people

with normal glucose tolerance, prediabetes, and type 2 diabetes, collected at baseline and 2 hours

after an oral glucose tolerance test, revealed tightly coregulated modules strongly associated with

glycemic dysregulation, insulin resistance, and islet dysfunction. Notably, short-chain organic

acids, particularly crotonic acid, emerged as hubs of the diabetes-associated networks,

accumulating progressively with disease severity. Reanalysis of extracellular vesicle proteomics

from the same cohort showed that 16.5% of circulating proteins were crotonylated, with

approximately 40% correlated with crotonic acid and other hub metabolites, establishing a

metabolome-crotonylome axis as a novel mechanism in diabetes development.

Introduction

Affecting hundreds of millions of people globally, type 2 diabetes mellitus (T2D) and

prediabetes are metabolic disorders that have reached epidemic proportions worldwide [1, 2].

T2D is a common metabolic disorder characterized by pancreatic β-cell dysfunction and insulin

resistance, resulting in hyperglycemia leading to an increased risk of complications ranging from

neuropathy and retinopathy to cardiovascular disease [3-5]. Prediabetes is a precursor to T2D

and is characterized by glycemic levels that exceed normal ranges yet remain below the diabetes

threshold [6]. The global prevalence of prediabetes and type 2 diabetes continues to rise, creating

a need for further studies to understand the pathogenesis of diabetes development and

progression [7, 8].

In the past, metabolomics has been applied to the study of diabetes to uncover novel biomarkers,

increase our understanding of diabetes pathophysiology, and develop better therapeutics and

interventions [9]. Compared to genomics and proteomics, metabolomics has proven itself as a

more reliable method of biomarker identification due to increased accuracy in identifying

pathophysiological changes within cells and systems [10, 11]. Additionally, studies have shown

that combining metabolomic data with clinical data and other omic technologies such as

proteomics enhances the predictive performance and clinical utility [12] as well as the study of

causal associations [13]. Previous metabolomics studies have consistently identified

branched□chain amino acids, aromatic amino acids such as phenylalanine, and metabolites

involved in carbohydrate and lipid metabolism as central components of the metabolic signature

associated with insulin resistance and diabetes pathogenesis [14-18]. Notably, a recent 2026

landmark metabolome-wide association study integrating 469 metabolites in 23,634 prospective

participants from 10 prospective cohorts identified 235 circulating metabolites associated with

incident T2D risk, including 67 previously unreported associations spanning glycine/serine, bile

acid, carnitine, and lipid pathways [19]. However, this effort did not address the coregulated

network architecture of the metabolome and its dynamic response to glucose. Complementary

evidence from the IMI-DIRECT study (n=3,000) previously identified novel markers of

glycemic deterioration, including 3,4-dihydroxybutyric acid and N-lactoyl amino acids, pointing

to understudied metabolites beyond the canonical branched-chain amino acids and lipid

biomarkers as contributors to diabetes progression [20]. In general, many of these prior studies

have only detected small subsets of metabolites and analyzed a limited metabolome under fasted

conditions. Our research extends beyond these studies by providing a global unbiased outlook of

the human metabolome in response to an oral glucose tolerance test (OGTT) and comparing this

to baseline conditions in participants with normal glucose tolerance, prediabetes and established

diabetes, providing unique insight on metabolomic changes across the spectrum of dysglycemia.

We specifically employed liquid chromatography-mass spectrometry (LC-MS/MS) technology

to conduct global metabolomic profiling due to its high sensitivity, comprehensive coverage, and

resolution [21]. This procedure has enabled us to gain a more comprehensive view of the human

metabolome and extends beyond the limitations of prior studies, which have only analyzed a

relatively small subset of metabolites. Additionally, we employed novel computational and

statistical methods, integrating metabolomic coexpression network analysis, extracellular vesicle

(EV) protein crotonylation analysis, differential expression analysis, and functional enrichment

analysis to discover complex metabolic signatures across the diabetes spectrum and elicit

mechanistic insight while assessing metabolite and protein network dynamics. Our analysis is

differentiated from prior metabolomics studies using OGTT samples due to the application of

coexpression network analysis, which takes advantage of the power-enhancing, naturally

occurring multiple correlations in metabolomic data [22] and the implementation of a multiomic

approach integrating the analysis of global EV proteomic data that serves as validation of key

metabolomic findings.

Results

Study Population

In this metabolomics study, a well-balanced subset of patients was carefully selected from the

ORIGINS (Uncovering the ORIGINS of Diabetes) study (ClinicalTrials.gov identifier:

NCT02226640). Our group has previously documented the parent study cohort [23]. In total, 30

participants were chosen (n=10 in each cohort: NGT, Pre-T2D, T2D), and confounding effects of

age, sex, and obesity were minimized in each cohort during selection. Serum samples were

obtained from the subjects at baseline and after OGTT (120min), and LC-MS/MS-based

untargeted metabolomics was performed on these serum samples from each of these subjects

before and a 2-h during the OGTT. This same cohort was previously used to identify proteomic

and phosphoproteomic signatures in circulating extracellular vesicles and dissect EV-mediated

mechanisms of diabetes development and progression [24]. The clinical characteristics of this

cohort are presented in Table 1.

Table 1. Tables should be placed in the main text near the first time they are cited.

	Healthy	**PreT2D**	**T2D**	**p**
n	10	10	10	
Sex = Male (%)	5 (50.0)	5 (50.0)	5 (50.0)	1.000
Age (years)	45.9 (10.5)	48.0 (7.8)	50.7 (11.0)	0.560
BMI (kg/m^2)	33.1 (6.5)	34.1 (5.6)	34.7 (5.2)	0.825
Weight Average (kg)	89.7 (16.7)	101.0 (15.6)	97.8 (21.4)	0.368
Height Average (cm)	165.4 (7.8)	172.8 (11.1)	167.5 (9.6)	0.223
Waist Circumference (cm)	99.6 (16.4)	110.8 (15.8)	109.63 (16.2)	0.252
DEXA Lean Mass (g)	52541.6 (8827.6)	56993.2 (12429.7)	54111.7 (12128.5)	0.672
DEXA Fat Mass (g)	34737.9 (16103.2)	41785.8 (15705.2)	41624.5 (12800.2)	0.494
DEX Fat Percentage (%)	38.3 (14.0)	41.7 (12.2)	43.0 (9.3)	0.672
HDL (mg/dL)	55.9 (11.8)	42.2 (8.9)	48.7 (16.6)	0.076
LDL (mg/dL)	113.7 (26.5)	113.6 (46.7)	102.3 (37.0)	0.741
Triglycerides (mg/dL)	105.0 (60.4)	159.7 (134.1)	139.5 (53.4)	0.404
TSH (mIU/L)	1.6 (0.7)	2.1 (1.1)	2.4 (1.1)	0.180
Temperature (F)	98.0 (0.3)	97.9 (0.4)	97.8 (0.2)	0.605
Respiration Rate (breaths per min)	14.7 (2.1)	15.5 (1.8)	15.2 (1.9)	0.646
Systolic Blood Pressure (mmHg)	124.4 (10.1)	125.2 (10.4)	126.0 (11.9)	0.950
Diastolic Blood Pressure	78.30 (9.1)	77.2 (9.9)	79.80 (8.2)	0.815

(mmHg)				
Heart Rate (beats per min)	63.4 (8.4)	71.0 (11.5)	67.6 (13.4)	0.340
HbA1C (%)	5.4 [5.3, 5.5]	5.9 [5.8, 6.1]	6.3 [6.1, 7.0]	0.001
Glucose baseline (mg/dL)	90.3 (6.7)	100.6 (8.2)	122.2 (20.3)	<0.001
Insulin baseline (μIU/mL)	3.6 (2.2)	8.6 (6.8)	5.8 (5.8)	0.134
Glucose AUC (mg/dL · min)	14797.3 [13302.1, 16433.5]	17202.3 [16488.6, 18909.1]	25796.2 [23196.5, 29180.5]	<0.001
Insulin AUC (μIU/mL · min)	3594.0 [2560.8, 7438.8]	6271.0 [2964.6, 11626.3]	3463.6 [2254.2, 4915.9]	0.237
C-peptide AUC (ng/mL · min)	694.2 [569.6, 820.0]	950.3 [573.5, 1262.8]	816.4 [687.6, 887.7]	0.783
Insulinogenic Index ($\Delta Ins_{0\text{-}30min}/\Delta Glu_{0\text{-}30min}$)	0.9 (0.6)	0.3 (3.0)	0.2 (0.2)	0.623
HOMA IR	0.8 (0.5)	2.1 (1.5)	2.0 (2.2)	0.155
HOMA_B	51.5 (36.4)	96.0 (107.6)	30.7 (22.5)	0.102
MATSUDA	12.2 (9.4)	6.3 (5.5)	9.7 (8.9)	0.276
AIRg	468.6 (349.8)	549.32 (530.1)	48.75 (64.6)	0.041
Si	4.6 (4.5)	2.7 (2.9)	4.6 (2.6)	0.434
DI	1150.7 (494.2)	890.3 (569.4)	249.5 (348.3)	0.005

Data presented as Mean (Standard Deviation) or Median [Interquartile Range]. Sex as number of males (%)

Global Serum Metabolomics of the Diabetes Spectrum

By conducting LC-MS/MS untargeted metabolomic profiling on the serum samples, we detected a total of 15,470 metabolite features, known and unknown, across all samples. Multiple data acquisition modes were used to detect these metabolites, including the positive and negative modes of HILIC and reverse phase C18. The expression of metabolites detected in more than one mode was averaged. Of the 15,470 metabolite features, 900 were known and 709 were known and detected in more than 70% of the samples. This subset of 709 known metabolites was used in subsequent analyses to identify differentially expressed metabolites and construct coexpression networks.

Coexpressed Metabolite Networks Associated with Diabetes Traits at Baseline and in Response to OGTT

To fill a gap dissecting the complex metabolic networks at play during diabetes development, we

conducted an analysis of metabolite coexpression networks using WGCNA [25]. Using the

WGCNA wrapper *BioNERO* [26], key metabolite modules were identified at baseline and 2

hours after an oral glucose tolerance test. In particular, we focused on a "Baseline" network that

mapped metabolite associations at time zero of an oral glucose tolerance test and a "Delta"

network that mapped the metabolite changes from baseline to 2-hours during the glucose

tolerance tests (Figure 1). We assigned particular importance to network modules that correlate

with clinical and physiological traits relevant to the progression of diabetes (Figure 2).

Specifically, we identified 11 modules in the Baseline network and 9 modules in the Delta

network (Figure 1). Some of these modules, like the Baseline Greenyellow and the Delta Purple

modules, and the Baseline Black and the Delta Yellow modules, overlapped between the two

networks (see the cross-tabulation of modules metabolites to infer correspondence between the

Baseline and Delta modules, Figure 1E).

Of note, eight of the Baseline modules (black, blue, brown, green, magenta, pink, purple, red)

were significantly ($P < 0.05$) correlated with at least one of the following diabetes-related traits:

diabetes group, fasting glucose, area under curve for glucose (AUC-Glucose), HbA1c, HOMA

IR, fasting insulin, disposition index, and glucose effectiveness (Figure 2). On the other hand, the

Delta Black module correlated with several glycemic control traits [i.e., AUC-Glucose (r=0.52,

P<0.01), HbA1c (r=0.38, P<0.05), and the Diabetes group (r=0.53, P<0.01)], while the Delta

Blue module negatively correlated with AUC-insulin (r=-0.38, P<0.05). The Delta Black and

Delta Blue modules segregated with the key Baseline Magenta module (see cross-tabulation of

modules metabolites in Figure 1E). Both the Delta Black and Delta Blue modules showed

substantial overlap (39 metabolites, $p = 2x10^{-25}$ and 15 metabolites, $p = 1x10^{-7}$, respectively)

with the Baseline Magenta module and were significantly correlated with relevant clinical

measures. This suggests that the coregulated metabolites from the Baseline Magenta module

segregate into two main global pathways in response to the oral glucose challenge, with

relevance to diabetes pathophysiology. Also notable is the fact that short/medium-chain organic

acids are key hub metabolites in these modules associated with the diabetes trait and measures of

glycemic control and insulin secretion and action. Among those short-chain organic acids were

aldehyde acids (e.g, glyoxylic acid), ketoacids (e.g, acetoacetic acid), and short-chain fatty acids

(SCFA: e.g, crotonic acid and 3S,4-dihydroxy-butyric acid), among others (Figure 3).

According to the module preservation analysis computed by BioNERO, the Baseline Magenta

module (comprised of n=86 metabolites) is, overall, the top most preserved module from the

Baseline network, as compared to the modules in the Delta network (Figure 1F). This means that

the majority of correlations among Magenta module metabolites remains after the glucose

challenge. Importantly, the Baseline Magenta module displayed a coexpression pattern that was

highly significantly correlated with the diabetes trait (r=0.66 P=6.5×10^{-5}), AUC-glucose (r=0.73

P<0.001), and negatively correlated with measures of glucose effectiveness (Sg, r=0.52, P<0.01)

(Figure 2A), among other relevant variables.

Another notable Baseline module was the Green module (n=55), which also strongly correlated

with the diabetes trait (r=0.62, P=2.4×10^{-4}) and glycemic control measures. The moderate

preservation score for this module likely indicates a network of diabetes-associated metabolites

that undergo a more heterogeneous response to the OGTT challenge. In analyzing the

metabolites in the Baseline Green (B), several lipid species, including various

glycerophospholipids (GPA, GPCho, PA, PC, PG), diacylglycerols (DG), and ceramide

phosphates (CerP) emerged as potentially relevant hubs (Figure 3B) in diabetes pathophysiology.

Notably, many of these lipid species contain polyunsaturated fatty acid chains of various chain

lengths, suggesting potential involvement in cell membrane dynamics and lipid signaling

pathways. Both the Baseline Magenta and Baseline Green modules showed dynamic shifts

across their metabolite composition in response to the glucose challenge, affecting about half of

the detected metabolites and segregating into multiple Delta modules (Figure 1E).

On the other hand, the Baseline Pink module positively correlated with beta cell function

measures and represents the most divergent module in response to the glucose challenge (Figure

1F). This module is characterized by the presence of hub metabolites such as N-methylputrescine,

agmatine, and piperidine 2-carboxamide (Figure 3C) that are protective against diabetes and

appears to be involved in mitochondrial beta oxidation of very long chain fatty acids (VLCFAs)

consistent with fatty acid metabolism. As shown in Figure 1C and 2A, the Baseline Pink and the

Baseline Red modules appear to be related based on their correlation distance and to coalesce

into the Delta Magenta module, which suggests coregulated changes in response to the glucose

challenge. The Baseline Red module is also enriched in metabolites related to beta oxidation, in

this case, of branched-chain fatty acids (BCFAs), and in metabolites of the carnitine synthesis

pathway (Figure 3D).

Distinct Metabolic Pathways were Enriched in Diabetes-related Modules

To characterize the biological mechanisms and pathways underlying the identified coregulated

modules, we conducted metabolite set enrichment analysis (MSEA) using the MetaboAnalystR

software [27]. This tool maps the metabolites from each module to their corresponding

annotation on The Small Molecule Pathway Database (SMPDB)'s comprehensive repository of

metabolic pathways, enabling us to assign functional context to these modules and to identify

specific pathways that are perturbed or enriched in relation to the studied experimental

conditions [28].

Enrichment analysis revealed several biological pathways and mechanisms related to the

modules found in the Baseline and Delta networks, highlighting the dynamic metabolic response

when faced with a glucose challenge (Figure 4, 5). The Baseline Magenta module was

significantly enriched (P<0.05, FDR<0.2) for glycine and serine metabolism, the citric acid cycle,

amino sugar metabolism, and the transfer of acetyl groups into mitochondria (Figure 4A).

Showing a similar pattern to the Baseline Magenta module, the Delta Black module was most

significantly enriched (P<0.05, FDR<0.2) not only for glycine and serine metabolism, the citric

acid cycle, and the transfer of acetyl groups into mitochondria, but also for Warburg effect

metabolites, ketone body metabolism, alanine and butyrate metabolism, degradation of BCAAs,

and carnitine synthesis (Figure 4B).

Differential abundance and interaction analysis of serum metabolites supports the progressive

accumulation of organic acids and their derivatives in prediabetes and diabetes.

To complement WGCNA and identify metabolite signatures that significantly changed (absolute

fold change FC>1.5, P<0.05, FDR<0.05) among the study groups, we conducted differential

abundance analysis using linear models that assessed both the main group effects at baseline and

OGTT-120min, as well as the group-by-time (GxT) interaction effects (which test whether the

molecular response to the glucose challenge differs across the glycemic spectrum), providing

insight into the distinct physiological response to a glucose challenge in people with prediabetes

and T2D, compared to normoglycemic individuals. Figures 6A and 6B and Supplementary

Materials Tables S1-S9 display the signatures of all differentially abundant metabolites and

metabolites with significant GxT interactions. Notably, all the hub metabolites identified in the

Baseline Magenta module had significant GxT interaction. A majority of these Magenta module

hub metabolites are short/medium-chain organic acids, including crotonic acid, glyoxylic acid,

3S,4-dihydroxy-butyric acid (DHBA), glyceric acid, and acetoacetic acid (Figure 3A and Figure

6C). Similarly, all but one of the hub metabolites in the Delta Black module belong to this group

of metabolites with significant GxT interaction: crotonic acid, glyoxylic acid, 3S,4-dihydroxy-

butyric acid, and glucoheptonic acid (Figure 3E and Figure 6C). The present overlap between

these distinct analyses underscores the important role of these organic acids in diabetes.

Interestingly, one small peptide with the sequence Leu-Arg-Thr-Gln-Val was the only metabolite

that displayed significant GxT interaction in the prediabetes group (compared to the response of

the NGT group) under our stringent significance criteria (Figure 6C, Supplementary Materials

Table S3).

Because DHBA is an intermediate in GABA metabolism, we also confirmed that GABA was

significantly elevated in the T2D (although below our FC cutoff of 1.5, with FC=1.34, P=0.012,

FDR=0.034), and that the metabolites display strong correlations at both baseline (r=0.45,

P=0.013) and after the glucose challenge (r=0.4, P=0.03), as shown in Figure 7.

Crotonylated proteins detected in serum extracellular vesicles significantly correlate with

differentially abundant and hub metabolites including crotonic acid.

Our results suggesting that crotonic acid plays a central role in diabetes, led us to reason that

protein crotonylation should also be affected in diabetes and associated with the metabolomic

signature. To validate this, we reanalyzed our previously published LC-MS/MS EV proteomic

data [24] to identify the crotonyl post-translational modification in the EV proteins. Our rationale

was that EVs represent, to some extent, a mirror image of their cells of origin, containing many

of the proteins present in these cells in proportional concentrations, which are used for

intercellular and inter-organ communication purposes. Other EV proteins destined for disposal

may appear to be loaded in disproportionate concentrations. By quantifying crotonylated proteins

in circulating EVs, we could gain insight into the systemic levels of crotonylated protein and

their association with coregulated metabolite networks and clinical measurements.

Notably, we found that 397 serum EV proteins (16.5% of the detected global EV proteome) were

crotonylated. Approximately two thirds (64% and 63%, respectively) of these EV crotonylated

proteins tend to increase their levels in both prediabetes and T2D, as compared to the NGT group

(Supplementary Materials Tables S10-S11). Because the ORIGINS study was not designed to

assess global significance of crotonylated proteins, this impacted our statistical power to identify

EV crotonylated proteins passing our stringent significant cutoffs after multiple testing

correction for the group comparisons. However, we did found that 189 (roughly half the set) of

those EV crotonylated proteins significantly (absolute /r/>0.4, P<0.05, FDR<0.1) correlated with

the baseline levels of 166 network hub and significant differentially abundant metabolites

(generating a total of 1,521 significant correlations, Supplementary Materials Table S12) that

defined key global metabolic pathways associated with clinical measures of glucose control and

beta cell function and that responded to the physiological glucose challenge. Serum levels of

several crotonylated EV proteins significantly correlated with the serum levels of crotonic acid

itself (Figure 8, Supplementary Material Table S13).

Discussion

The present study provides one of the most comprehensive serum metabolomic characterization

of the human diabetes spectrum to date, uncovering coregulated networks of metabolites that

underlie the development of prediabetes and type 2 diabetes. A central and novel finding is that

short-chain organic acid hubs, with a prominent role of crotonic acid, progressively accumulate

with diabetes severity and appear to be mechanistically linked to global protein crotonylation in

circulating EVs. This integrative multiomic approach, combining coexpression metabolomic

network analysis with EV proteomics, reveals that the diabetic metabolome exerts a broad

influence on the post-translational landscape of circulating EV proteins, offering a new

mechanistic perspective on diabetes pathophysiology.

The coexpression network modules most significantly associated with diabetes correlated with

glycemic control (fasting glucose, HbA1c, AUC-glucose), insulin resistance (HOMA-IR), and

islet function (disposition index, AUC-insulin), and contained well-established diabetes

metabolites such as branched-chain amino acids, aromatic amino acids (tyrosine, phenylalanine),

glutamic acid, aminoadipic acid, ceramides, diacylglycerols, and bile acids among others, which

provide cross-validation against the existing literature [14, 15, 29-35] and the recent 235

metabolites prospectively associated with incident T2D over 26 years of follow-up in 23,634

individuals [19]. Importantly, the Baseline Magenta module, the most strongly preserved module

across both networks, segregated in response to the glucose challenge into two complementary

Delta modules: the Delta Black (correlated with glycemic control) and Delta Blue (correlated

with insulin secretion). This dissection suggests that the Baseline Magenta module encompasses

two physiologically distinct subnetworks: one reflecting pancreatic endocrine function and one

reflecting the composite metabolic response of the liver, muscle, and adipose tissue, that together

constitute a central metabolic pathway of diabetes development.

A common feature of the Baseline Magenta and Delta Black modules is their enrichment in

short-chain organic acid hubs that accumulate progressively in prediabetes and T2D, most

prominently following the glucose challenge (particularly in the T2D group). This accumulation

contrasts with a concurrent deregulation in the Baseline Pink and Red modules, which are

enriched in mitochondrial beta-oxidation of very-long-chain and branched-chain fatty acids

(VLCFAs/BCFAs), and are consistent with reports of impaired VLCFA catabolism in diabetes

[36-39]. Together, these findings suggest a coordinated metabolic shift in which accumulating

short-chain organic acids drive pathological network hubs while the long-chain fatty acid

oxidation machinery becomes progressively impaired. In addition, and consistent with our

identification of glycine and serine degradation as a prominently enriched pathway in the top

diabetes-associated Baseline Magenta and Delta Black modules, a recent large-scale

metabolome-wide association study independently identified glycine and L-serine metabolism as

the top canonical pathway enriched among genetic loci of T2D-associated circulating

metabolites, and further showed that circulating glycine mediates part of the protective

association between coffee/tea consumption and incident T2D risk [19].

Crotonic acid hub and a novel role for global protein crotonylation in diabetes: Among the most

relevant short-chain organic acid hubs, identified by our study, was crotonic acid. Crotonic acid

is a short-chain, unsaturated carboxylic acid that serves as the substrate for protein crotonylation,

a post-translational modification first described in 2011, in which crotonyl groups are added to

lysine residues [40]. Like butyrate, crotonic acid is likely derived from gut microbiota and once

transported into cells via monocarboxylate transporters, it is converted to crotonyl-CoA for

protein modification [41, 42]. Although crotonylation has been linked to kidney disease,

neurological disorders, and cancers [41], its role in diabetes had not been established. Our study

reveals that crotonic acid is a differentially abundant and progressively accumulating hub

metabolite in the diabetes-associated network modules. To assess downstream effects, we

identified 397 (16.5%) crotonylated serum EV proteins, of which approximately 40%

significantly correlated with hub metabolites including crotonic acid. These correlations are

remarkable given the signal dilution expected in circulation, where many cell types contribute

metabolites and EVs. Recent mechanistic studies provide compelling support. For example, Liu

and colleagues showed that increased global protein crotonylation promotes white fat browning

and activates mitochondrial energy metabolism proteins (AK2, Tpi1, NDUFA8) [43], potentially

explaining increased resting energy expenditure reported in insulin-resistant conditions and in

people with poor beta cell function [44, 45]. In addition, Liao and Zhang demonstrated that

EPB41L4A-AS1, a long non-coding RNA elevated in T2D liver and insulin-resistant muscle,

inhibits GLUT4 expression by reducing H3K27 crotonylation at the GLUT4 promoter [46]; and

Shan et al. showed that *Enteromorpha prolifera* oligosaccharide (EPO) improves glucose

metabolism by inhibiting HSPA8 crotonylation and activating the AKT pathway, while XPO1

crotonylation promotes cellular oxidative damage and aging [47]. Together, these findings

establish elevated crotonic acid and consequent global protein crotonylation as a central,

previously underappreciated mechanism in diabetes development and/or progression.

Glyoxylic acid (glyoxylate): Glyoxylic acid was a differentially abundant hub in both the

Baseline Magenta and Delta Black modules. Produced via peroxisomal oxidation of glycolate or

mitochondrial catabolism of hydroxyproline [48, 49], glyoxylate has emerged as a metabolic

biomarker of T2D risk, with increased circulating levels detected up to 3 years prior to diagnosis

[50]. In addition, elevated levels of glyoxylate are hypothesized to link excess fatty acid-to-

glucose conversion to insulin resistance [50, 51]. Its co-elevation with arachidonic and dihomo-

gamma linolenic acids in antihypertensive-treated T2D patients has been attributed to suppressed

alanine:glyoxylate aminotransferase (AGT1/2) activity, linking glyoxylate to the intersection of

diabetes and hypertension [52]. Our network-level identification of glyoxylate as a diabetes-

associated hub reinforces its candidacy as an early biomarker and mediator of metabolic

dysregulation warranting further validation.

3S,4-dihydroxy-butyric acid (3,4-DHBA): 3,4-DHBA, an intermediate in GABA metabolism and

a hub in both the Baseline Magenta and Delta Black modules, was among the most significantly

differentially abundant metabolites in our cohort. Given that GABA is produced in high

concentrations by pancreatic beta cells [53], and that we confirmed elevated GABA in T2D

(FC=1.34, P=0.012, FDR=0.034), the correlated accumulation of 3,4-DHBA and GABA in

circulation suggests impaired pancreatic GABA clearance likely associated with disruption of

mitochondrial oxidative function [54]. Recent independent validation for 3,4-DHBA as a

biomarker of glycemic deterioration is provided by its significant association with HbA1c

progression rate in the IMI-DIRECT cohort (n=3,000; β=0.060, FDR=0.00864) [20], confirming

that this metabolite's relevance extends beyond our cohort and across distinct study populations

and metabolomic platforms. Additionally supporting its clinical relevance, 3,4-DHBA levels

correlate with the stage of diabetic retinopathy and predict its longitudinal progression [55]. A

Mendelian randomization study further implicated Christensenellaceae gut bacteria in elevated

circulating 3,4-DHBA levels [56], suggesting this metabolite may bridge gut dysbiosis, diabetes,

and its complications. Furthermore, the association of GABA with incident T2D risk [Hazard

Ratio=1.07 (95%CI: 1.01-1.13), P=0.013, FDR=0.022] was also recently identified in a

prospective metabolome-wide association study of 23,634 participants [19], which combined

with our finding of co-elevated circulating GABA and 3,4-DHBA in prediabetes and T2D, adds

support for the relevance of pancreatic GABA dysregulation as a feature of the diabetic state

detectable in circulation.

4-imidazolone-5-propionic acid (imidazole propionate): Imidazole propionate, a hub in our

diabetes-associated modules, has been shown to impair insulin signaling through activation of

the p38γ/p62/mTORC1 pathway and to inhibit metformin-induced AMPK activation, thereby

reducing the hypoglycemic efficacy of metformin [57, 58]. Its association with the Bacteroides 2

enterotype and reduced gut bacterial gene richness implicates gut dysbiosis as an upstream driver

of its accumulation [59], and polysaccharides from mulberry leaves that improve glycemia in

diabetic rat models downregulate imidazole propionate among other metabolites [60]. Together

with crotonic acid and glyoxylic acid, our data support a model in which gut microbiota-derived

short-chain organic acids drive interconnected network hubs that impair insulin signaling and

promote glucose dysregulation across the diabetes spectrum.

Small peptide biology: Among additional novel findings, two micro-peptides, namely Ala-Asp-

Gly-Gly (ADGG) and Leu-Arg-Thr-Gln-Val (LRTQV), displayed significant group-by-time

interaction effects, with LRTQV showing a significant negative interaction selectively in the

prediabetes group under our most stringent criteria. The structural features of these peptides

suggest potential ligand activity: glycine's flexibility facilitates induced-fit binding by small

molecules [61], arginine and aspartate contribute to integrin-binding RGD-like motifs [62], and

threonine hydroxyl groups enable receptor hydrogen bonding [63]. These micro-peptides

represent potentially tractable biomarkers of early prediabetes and/or diabetes and warrant

further investigation.

The main limitation of this study is the relatively small sample size (n=30 x 2 timepoints).

However, the dynamic assessment of responses to a physiologically relevant glucose challenge,

the deep phenotyping of the ORIGINS cohort, and the unparalleled depth of metabolomics

profiling (>700 annotated metabolites consistently detected) substantially strengthen the

biological relevance of the statistically significant findings reported here.

Altogether, this study identifies molecular networks underlying the development of prediabetes

and type 2 diabetes, with short-chain organic acids (centered on crotonic acid) forming the

pathophysiologically relevant network hubs. The progressive accumulation of crotonic acid,

glyoxylic acid, 3S,4-dihydroxybutyric acid, imidazole propionate, and related organic acids,

paired with deregulated long-chain fatty acid oxidation and altered amino acid metabolism,

constitutes a composite metabolic signature of the diabetic state. The validation of this signature

through its association with global protein crotonylation in circulating EV proteins establishes a

mechanistic link between the serum metabolome and a broad post-translational modification

program with demonstrated relevance to insulin signaling and glucose metabolism. Consequently,

a unifying hypothesis develops: diabetes may involve coordinated subclinical deficiencies in the

metabolism of glycine, serine, GABA, branched-chain amino acids, and short-chain fatty acids

that collectively alter global protein crotonylation and impair glucose regulation. Future

investigations in larger cohorts are needed to validate these hub metabolites as therapeutic targets,

biomarkers of progression and/or response to treatment, and/or biomarkers for early detection in

prediabetes and type 2 diabetes.

Materials and Methods

Sample Selection and Criteria

The AdventHealth Institutional Review Board approved all procedures. Prior to commencing the

study, all volunteers provided informed consent. The study leveraged archived serum samples

and richly annotated clinical data from 30 human subjects with 10 individuals per group from the

ORIGINS (Uncovering the ORIGINS of Diabetes) study (ClinicalTrials.gov identifier:

NCT02226640). ORIGINS is a deeply phenotyped observational cohort designed to elucidate

molecular heterogeneity across the diabetes spectrum through integrated metabolic, clinical, and

multiomic characterization. The groups were comprised of individuals with normal glucose

tolerance (NGT), prediabetes (PDM), or type 2 diabetes (T2D), as defined by the American

Diabetes Association [64]. Subjects with type 1 diabetes or any other form of diabetes were

excluded as per the ORIGINS study criteria. The participants were selected to assure the groups

were well-balanced for age, sex, and obesity and were chosen through a partially automated

process that utilized a custom script based on the *MatchIt* package in the R programming

environment. This same cohort was used for our previous EV proteomic and phosphoproteomic

study [24].

Clinical Measurements

Standardized protocols were followed to obtain the clinical and metabolic measurements of the

study subjects [24]. Body composition was assessed by dual-energy x-ray absorptiometry (DXA,

GE Lunar iDEXA, Madison, WI, USA). Fasting blood samples were collected, and a 75 g OGTT

was conducted over a 2-hour period. On a separate visit, an insulin-modified frequently sampled

intravenous glucose tolerance test (FSIVGTT) was carried out. Plasma glucose levels were

measured using the glucose oxidase method on a YSI 2300 STAT Plus Analyzer (YSI Life

Sciences, Yellow Springs, OH, USA). Plasma insulin and C-peptide concentrations were

determined utilizing the MSD human insulin assay kit and C-peptide kit, respectively (MSD,

Rockville, MD, USA). HbA1c levels were measured by means of a Cobas Integra 800 Analyzer

(Roche, Basel, Switzerland). β-cell function was evaluated by computing HOMA-B, the

insulinogenic index [ΔIns0–300/ΔGluc0–300], and the insulin and C-peptide areas under the

curve (AUC) in response to OGTT. HOMA-IR was calculated as previously described to assess

insulin activity [65, 66]. Data obtained from the FSIVGTT were utilized to determine insulin

sensitivity (Si) and acute insulin response to glucose (AIRg) using the Minimal Model method

by Bergman [67, 68].

Metabolomics profiling

Plasma metabolites were extracted from 50 ul of plasma with 80% (1:1) MeOH:ACN containing

^{13}C phenylalanine as an internal standard, and centrifuged at $10,000 \times g$ for 30 min at 4 °C.

The supernatants were dried and resuspended in 50 µL of 50% acetonitrile/water for analysis

using a Q Exactive Plus Orbitrap MS (QE MS) equipped with an HESI II probe and coupled to

an Ultra High Pressure Liquid Chromatography system (Dionex UltiMate 3000). Samples were

analyzed within 24 hours of reconstitution. Four modes (2x2 matrix) were implemented: HILIC

and Reverse Phase C18 columns, both with positive and negative electrospray ionization. For

quality control (QC) of samples, the Standard Reference Material SRF1950 was used, and three

pooled serum samples were prepared from 10 uL aliquots from all samples in each subgroup

(n=10). Reverse-phase (RP) chromatography was performed using an HSS C18 column (150 3

2.1 mm i.d., 1.7 mm; Waters) with a flow rate of 0.4 mL/min. Solvent A was 0.1% formic acid in

water, and solvent B was 0.1% ACN. The LC gradient included a 1-minute hold at 0.1% B,

followed by a ramp from 0.1% to 50% B over the next 7 minutes, and then a ramp to 99% over

the following 8 min. A 3 min hold at 99% was followed by a return to 0% over the next 0.5 min.

The run was completed with a 7 min reconditioning at 0.1% B. The RP separation was

performed over 22 min in positive ionization mode. The mass spectrometer was operated in

positive and negative ESI ion mode in the scan range of m/z 70 to 1,050 with the resolution of

70,000 at m/z 200, automatic gain control (AGC) target at 1.3×10^6, and maximum injection

time of 50 ms. The spray voltage was set to 3.5 and 2.5 kV in positive and negative ion mode,

respectively. The heated capillary was set at 200°C, the HESI probe was set at 350°C, and the S-

lens RF level was set at 45. The gas settings for sheath, auxiliary, and sweep were 40, 10 and 1

unit, respectively. Peak areas (AUC) were used for comparative quantitation. RAW data files

were processed with Xcalibur Quan software (Thermo Scientific) and Progenesis Qi (Waters) for

filtering, alignment, feature detection, normalization, and annotation of the LC-MS signals.

Putative metabolite ID was based on accurate mass (error<10 ppm) as compared to Metlin &

NIST databases. Area counts for each analyte were used for analysis. For statistical analysis of

the metabolomic data, the means of the quadruplicate measurements (one from each LC-MS

mode) were used.

Weighted Coexpression Network Analysis

Weighted gene correlation network analysis, or WGCNA, is an algorithm and R package that

identifies clusters of interrelated genes using graphs and networks composed of pairwise

correlations of expression levels [25]. While WGCNA is primarily used for analyzing genomic

data, we applied the algorithm towards metabolomic data. This scenario is not an uncommon use

case, and prior research has shown WGCNA to be a suitable and unique method of analyzing

metabolomic data [69]. Rather than focusing on individual metabolites, as in traditional

differential abundance analyses, WGCNA takes advantage of the underlying correlations

between metabolites and groups metabolites that show similar expression patterns and are

directly or indirectly related to one another. These sets of related metabolites are then assigned to

modules, which are correlated to clinical variables to determine trait significance and module

membership, providing valuable clinical insight.

Following the procedure outlined by Almeida-Silva, et al. in the *BioNERO* R package (a

streamlined library for WGCNA [26]) documentation, we constructed signed coexpression

networks and identified modules for the Baseline metabolite measurement dataset (n = 30, 10 in

each cohort) and the Delta metabolite measurement dataset (n=30, 10 in each cohort), which

represents the difference in expression of metabolites at OGTT-120min and Baseline. The

datasets all contained measurements of the 709 identifiable metabolites at their respective

timepoints. This process resulted in two different coexpression networks, each with their own

unique modules.

The module identification process began with inputting and cleaning the datasets (quantile

normalization, outlier identification, etc.). Next, a soft power of $\beta = 5$ and 12 was calculated for

the Baseline and Delta datasets on the basis of scale-free topology, respectively. The co-

expression similarity was raised to this power to calculate adjacencies. Topological overlap

matrices were then calculated from the adjacency matrices, allowing for both direct and indirect

relationships between metabolites to be gathered. The deepSplit parameter was set to 2, and a

minimum module size of 10 metabolites was used. Hierarchical clustering was employed to

generate dendrograms displaying metabolite relationships, and this tree was subsequently cut

(height = 0.25) to determine relevant metabolite modules. Lastly, the identified modules in

Baseline and Delta were correlated with clinical variables. Furthermore, modules of metabolites

with significant ($p < 0.05$) correlations to diabetes-relevant clinical traits (diabetes group, C-

peptide, HbA1c, glucose levels, HOMA-IR, etc.) were selected for downstream analyses.

Metabolite Set Enrichment Analysis

Metabolite set enrichment analysis (MSEA) was performed using the enrichment analysis R

package MetaboAnalystR [27]. Specifically, MSEA was conducted on each of the significant

modules identified in the baseline and delta datasets to determine biological pathway and

mechanistic relevance. The list of 709 identified metabolites was used as the background

metabolite set. The accepted descriptions for these metabolites were matched to their Small

Molecule Pathway Database (SMPDB) IDs [28]. Correspondingly, the SMPDB metabolic

pathways were chosen as the metabolite set library for matching.

Extracellular Vesicle (EV) Proteomics and Protein Crotonylation Analysis

Our group previously reported mass spectrometry methods used for EV proteomic profiling of

the same serum samples used in this metabolomic study [24]. Because crotonic acid was one of

the key metabolites uncovered by this study (results to be presented later in this manuscript), we

integrated the analysis of EV crotonylated proteins here. In brief, EVs were isolated using

EVtrap® technology from Tymora Analytical Operations, and proteins were identified and

quantified using an Ultimate 3000 nano UHPLC system (Thermo Fisher Scientific) coupled with

a Q-Exactive HF-X mass spectrometer (Thermo Fisher Scientific). The mass spectrometer was

operated in the data-dependent mode, and a full-scan MS (from m/z 375 to 1,500 with the

resolution of 60,000) was followed by MS/MS of the 15 most intense ions with a resolution of

30,000. The raw files were searched directly against the human UniProt database with no

redundant entries, using Byonic (Protein Metrics) and Sequest search engines loaded into

Proteome Discoverer 2.3 software (Thermo Fisher Scientific). MS1 precursor mass tolerance

was set at 10 ppm, and MS2 tolerance was set at 20 ppm. Search criteria to identify crotonylated

proteins included a mass shift (+68.0375 Da) associated with the addition of a crotonyl group to

lysine residues. The search was performed with full trypsin/P digestion and allowed a maximum

of two missed cleavages on the peptides analyzed in the sequence database. The false discovery

rates of proteins and peptides were set at 0.01. All protein and peptide identifications were

grouped, and any redundant entries were removed. Only unique peptides and unique master

proteins were reported.

Statistical Analysis

Metadata normality was tested using the Shapiro-Wilk test, and non-normal data were log-

transformed to approximate normality. Differences in baseline clinical characteristics were

assessed using the Welch two-sample t-test (for continuous variables) or the Fisher exact test (for

categorical variables). Analysis of differential abundance of metabolites and crotonylated

proteins was conducted using linear models implemented with the *limma* package [70]. The

linear models for the longitudinal OGTT metabolomics data included a group-by-time

interaction term to account for the potential group-specific differential effects in response to the

glucose challenge over time. To account for the correlation between the repeated measures at

baseline and OGTT-120min, *duplicateCorrelation* was calculated and used to model the random

effects of the Subject_ID variable. The design matrix was specified as:

```
design <- model.matrix(~ DM_Group + DM_Group:time, metadata),
```

508   where DM_Group has 3 levels (NGT = reference, PreT2D, T2D) and time has 2 levels ("0" =

509   reference, "120"). This is a reference-within-group interaction design. The key architectural

510   choice is the absence of a main effect for time. Using ~ DM_Group + DM_Group:time, instead

511   of ~ DM_Group * time, causes R to absorb the time effect entirely into the group:time

512   interaction terms, giving each group its own independent temporal slope from baseline [71, 72].

513   This parameterization estimates group□specific response trajectories rather than a pooled time

514   effect, which is preferable for longitudinal designs such as OGTT, where temporal dynamics are

515   expected to differ by group. The design columns interpretation is as follows:

#	Column	Interpretation
1	(Intercept)	Mean for NGT at time 0 (grand baseline)

2	DM_GroupPreT2D	PreT2D - NGT difference at time 0 (fasting)
3	DM_GroupT2D	T2D - NGT difference at time 0 (fasting)
4	DM_GroupNGT:time120	Within-NGT change from time 0 to 120 (OGTT response)
5	DM_GroupPreT2D:time120	Within-PreT2D change from time 0 to 120
6	DM_GroupT2D:time120	Within-T2D change from time 0 to 120

516 A full contrast matrix was then generated using the *makeContrasts* function of the *limma*

517 package to assess the relevant comparisons:

Contrast	Vector	Biological Question
PreT2D_vs_NGT.t0	[0, +1, 0, 0, 0, 0]	Fasting difference: PreT2D vs NGT
T2D_vs_NGT.t0	[0, 0, +1, 0, 0, 0]	Fasting difference: T2D vs NGT
T2D_vs_PreT2D.t0	[0, -1, +1, 0, 0, 0]	Fasting difference: T2D vs PreT2D
PreT2D_vs_NGT.t120	[0, +1, 0, -1, +1, 0]	Post-OGTT: PreT2D vs NGT
T2D_vs_NGT.t120	[0, 0, +1, -1, 0, +1]	Post-OGTT: T2D vs NGT
T2D_vs_PreT2D.t120	[0, -1, +1, 0, -1, +1]	Post-OGTT: T2D vs PreT2D
Interaction.PreT2D_vs_NGT	[0, 0, 0, -1, +1, 0]	Is PreT2D OGTT response != NGT?
Interaction.T2D_vs_NGT	[0, 0, 0, -1, 0, +1]	Is T2D OGTT response != NGT?
Interaction.T2D_vs_PreT2D	[0, 0, 0, 0, -1, +1]	Is T2D OGTT response != PreT2D?

518 The interaction terms are the highest-value contrasts as they test whether the molecular response

519 to the glucose challenge differs across the glycemic spectrum (NGT, Prediabetes, T2D). The

520 Benjamini-Hochberg correction, as implemented for the *p.adjust* function in the *stats* package,

521 was used to calculate the false discovery rate (FDR) and correct for multiple testing.

522 Metabolomic features with fold change FC>1.5, P<0.05, and FDR<0.05 were considered

523 significant. Correlations between serum metabolites and serum crotonylated EV proteins with

524 absolute r>0.4, P<0.05, and FDR<0.01 were considered significant.

526 **Data availability:** All data produced in the present study will be available upon reasonable

527 request to the authors after actual publication in peer-reviewed journal.

529 **Author Contributions:** REP and YNL designed and supervised the study. REP funded the study,

530 interpreted results, and critically reviewed the manuscript. YNL and DD wrote the R scripts,

531   analyzed data, interpreted results, and wrote the manuscript. TD conducted mass spectrometry

532   experiments for metabolomics, generated and analyzed data, interpreted results, and critically

533   reviewed the manuscript. AI conducted mass spectrometry experiments for EV proteomics,

534   generated data, interpreted results, and critically reviewed the manuscript. AC analyzed data,

535   interpreted results, contributed to manuscript writing, and critically reviewed the manuscript.

536   SJG supervised the metabolomics experiments, interpreted results, and critically reviewed the

537   manuscript.

539   **Funding:** This study was funded by program funds granted to REP by the AdventHealth

540   Translational Research Institute.

542   **Acknowledgements:** The authors thank Dr. Steven R. Smith for providing access to the archived

543   samples from the ORIGINS study.

545   **Competing Interests:** Dr. Pratley reports support from NIH research grants (U01DK106993,

546   R01DK138060, U01DK35131, R01DK143524, U01DK143384, U01DK127392). Investigator-

547   initiated grant support from Abbott Laboratories, Research grants (directed to his institution):

548   AstraZeneca AB, Biomea Fusion, Boehringer Ingelheim International GmbH, Carmot

549   Therapeutics, Dompe, Eli Lilly and Company, Endogenex, Inc., Fractyl, Lexicon, Metavention,

550   National Institutes of Health, Novo Nordisk, and Sanofi. Consultancy fees from: Abbott

551   Laboratories, AbbVie Inc., Altanine Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bayer

552   AG, Bayer HealthCare Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.,

553   Corcept Therapeutics Incorporated, Endogenex, Inc., F. Hoffmann-La Roche Ltd., Hanmi

554   Pharmaceutical Co., Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Response

555   Pharmaceuticals, Rona Therapeutics Ltd, Scholar Rock Inc., Sun Pharmaceutical Industries,

556   Third Rock Ventures, and Verdiva Bio Dev Limited, as well as speaker fees from Abbott,

557   Corcept, Lilly USA LLC and Novo Nordisk, and stock options from Altanine, Inc. Dr. Casu

558   reports research funding from Enable Biosciences directed to her institution. NIH research grant

559   U01 DK135131. All other authors declare no competing interests.

561   **References**

562   1.   Khan, M.A.B., et al., *Epidemiology of Type 2 Diabetes - Global Burden of Disease and*
563   *Forecasted Trends.* J Epidemiol Glob Health, 2020. **10**(1): p. 107-111.
564   2.   Hostalek, U., *Global epidemiology of prediabetes - present and future perspectives.* Clin
565   Diabetes Endocrinol, 2019. **5**: p. 5.
566   3.   Chatterjee, S., K. Khunti, and M.J. Davies, *Type 2 diabetes.* Lancet, 2017. **389**(10085): p.
567   2239-2251.
568   4.   Gilmer, T.P., et al., *Predictors of health care costs in adults with diabetes.* Diabetes Care,
569   2005. **28**(1): p. 59-64.
570   5.   Goyal, R., M. Singhal, and I. Jialal, *Type 2 Diabetes*, in *StatPearls*. 2025: Treasure Island
571   (FL).
572   6.   Vas, P.R.J., K.G. Alberti, and M.E. Edmonds, *Prediabetes: moving away from a*
573   *glucocentric definition.* Lancet Diabetes Endocrinol, 2017. **5**(11): p. 848-849.
574   7.   Tabak, A.G., et al., *Prediabetes: a high-risk state for diabetes development.* Lancet, 2012.
575   **379**(9833): p. 2279-90.
576   8.   Whiting, D.R., et al., *IDF diabetes atlas: global estimates of the prevalence of diabetes*
577   *for 2011 and 2030.* Diabetes Res Clin Pract, 2011. **94**(3): p. 311-21.
578   9.   Passaro, A.P., et al., *Omics era in type 2 diabetes: From childhood to adulthood.* World J
579   Diabetes, 2021. **12**(12): p. 2027-2035.
580   10.   Chen, R., et al., *LC-MS-Based Untargeted Metabolomics Reveals Early Biomarkers in*
581   *STZ-Induced Diabetic Rats With Cognitive Impairment.* Front Endocrinol (Lausanne),
582   2021. **12**: p. 665309.
583   11.   Milburn, M.V. and K.A. Lawton, *Application of metabolomics to diagnosis of insulin*
584   *resistance.* Annu Rev Med, 2013. **64**: p. 291-305.
585   12.   Klein, M.S. and J. Shearer, *Metabolomics and Type 2 Diabetes: Translating Basic*
586   *Research into Clinical Application.* J Diabetes Res, 2016. **2016**: p. 3898502.
587   13.   Chen, Z.-Z. and R.E. Gerszten, *Metabolomics and Proteomics in Type 2 Diabetes.*
588   Circulation Research, 2020. **126**(11): p. 1613-1627.
589   14.   Newgard, C.B., et al., *A branched-chain amino acid-related metabolic signature that*
590   *differentiates obese and lean humans and contributes to insulin resistance.* Cell Metab,
591   2009. **9**(4): p. 311-26.

592   15.   Wang, T.J., et al., *Metabolite profiles and the risk of developing diabetes.* Nat Med, 2011.
593   **17**(4): p. 448-53.

594   16.   Newgard, C.B., *Interplay between lipids and branched-chain amino acids in development*
595   *of insulin resistance.* Cell Metab, 2012. **15**(5): p. 606-14.

596   17.   Lynch, C.J. and S.H. Adams, *Branched-chain amino acids in metabolic signalling and*
597   *insulin resistance.* Nat Rev Endocrinol, 2014. **10**(12): p. 723-36.

598   18.   Merino, J., et al., *Metabolomics insights into early type 2 diabetes pathogenesis and*
599   *detection in individuals with normal fasting glucose.* Diabetologia, 2018. **61**(6): p. 1315-
600   1324.

601   19.   Li, J., et al., *Circulating metabolites, genetics and lifestyle factors in relation to future*
602   *risk of type 2 diabetes.* Nat Med, 2026. **32**(2): p. 660-670.

603   20.   Sharma, S., et al., *Role of human plasma metabolites in prediabetes and type 2 diabetes*
604   *from the IMI-DIRECT study.* Diabetologia, 2024. **67**(12): p. 2804-2818.

605   21.   Cui, L., H. Lu, and Y.H. Lee, *Challenges and emergent solutions for LC-MS/MS based*
606   *untargeted metabolomics in diseases.* Mass Spectrom Rev, 2018. **37**(6): p. 772-792.

607   22.   Steuer, R., *Review: on the analysis and interpretation of correlations in metabolomic*
608   *data.* Brief Bioinform, 2006. **7**(2): p. 151-8.

609   23.   Nunez Lopez, Y.O., G. Garufi, and A.A. Seyhan, *Altered levels of circulating cytokines*
610   *and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.* Mol
611   Biosyst, 2016. **13**(1): p. 106-121.

612   24.   Nunez Lopez, Y.O., et al., *Proteomics and Phosphoproteomics of Circulating*
613   *Extracellular Vesicles Provide New Insights into Diabetes Pathobiology.* Int J Mol Sci,
614   2022. **23**(10).

615   25.   Langfelder, P. and S. Horvath, *WGCNA: an R package for weighted correlation network*
616   *analysis.* BMC Bioinformatics, 2008. **9**: p. 559.

617   26.   Almeida-Silva, F. and T.M. Venancio, *BioNERO: an all-in-one R/Bioconductor package*
618   *for comprehensive and easy biological network reconstruction.* Functional & Integrative
619   Genomics, 2022. **22**(1): p. 131-136.

620   27.   Chong, J. and J. Xia, *MetaboAnalystR: an R package for flexible and reproducible*
621   *analysis of metabolomics data.* Bioinformatics, 2018. **34**(24): p. 4313-4314.

622   28.   Jewison, T., et al., *SMPDB 2.0: big improvements to the Small Molecule Pathway*
623   *Database.* Nucleic Acids Res, 2014. **42**(Database issue): p. D478-84.

624   29.   Felig, P., E. Marliss, and G.F. Cahill, Jr., *Plasma amino acid levels and insulin secretion*
625   *in obesity.* N Engl J Med, 1969. **281**(15): p. 811-6.

626   30.   Würtz, P., et al., *Branched-Chain and Aromatic Amino Acids Are Predictors of Insulin*
627   *Resistance in Young Adults.* Diabetes Care, 2013. **36**(3): p. 648-655.

628   31.   Floegel, A., et al., *Identification of Serum Metabolites Associated With Risk of Type 2*
629   *Diabetes Using a Targeted Metabolomic Approach.* Diabetes, 2013. **62**(2): p. 639-648.

630   32.   Wang-Sattler, R., et al., *Novel biomarkers for pre-diabetes identified by metabolomics.*
631   Mol Syst Biol, 2012. **8**: p. 615.

632   33.   Lee, H.J., et al., *2-Aminoadipic acid (2-AAA) as a potential biomarker for insulin*
633   *resistance in childhood obesity.* Sci Rep, 2019. **9**(1): p. 13610.

634   34.   Cheng, S., et al., *Metabolite profiling identifies pathways associated with metabolic risk*
635   *in humans.* Circulation, 2012. **125**(18): p. 2222-31.

636   35.   Wang, T.J., et al., *2-Aminoadipic acid is a biomarker for diabetes risk.* J Clin Invest,
637   2013. **123**(10): p. 4309-17.

638 36. Guasch-Ferré, M., et al., *Metabolomics in Prediabetes and Diabetes: A Systematic*
639 *Review and Meta-analysis.* Diabetes Care, 2016. **39**(5): p. 833-846.
640 37. Erdbrügger, P. and F. Fröhlich, *The role of very long chain fatty acids in yeast physiology*
641 *and human diseases.* Biological Chemistry, 2021. **402**(1): p. 25-38.
642 38. Lu, Q., et al., *The Overlooked Transformation Mechanisms of VLCFAs: Peroxisomal β-*
643 *Oxidation.* Agriculture, 2022. **12**(7): p. 947.
644 39. Yamada, K. and T. Taketani, *Management and diagnosis of mitochondrial fatty acid*
645 *oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.* J
646 Hum Genet, 2019. **64**(2): p. 73-85.
647 40. Tan, M., et al., *Identification of 67 histone marks and histone lysine crotonylation as a*
648 *new type of histone modification.* Cell, 2011. **146**(6): p. 1016-28.
649 41. Yang, P., et al., *Crotonylation and disease: Current progress and future perspectives.*
650 Biomedicine & Pharmacotherapy, 2023. **165**: p. 115108.
651 42. Liao, P., et al., *Crotonylation at serine 46 impairs p53 activity.* Biochemical and
652 Biophysical Research Communications, 2020. **524**(3): p. 730-735.
653 43. Liu, Y., et al., *Non-Histone Lysine Crotonylation Is Involved in the Regulation of White*
654 *Fat Browning.* International Journal of Molecular Sciences, 2022. **23**(21): p. 12733.
655 44. Quaye, E., et al., *Energy expenditure due to gluconeogenesis in pathological conditions*
656 *of insulin resistance.* American Journal of Physiology-Endocrinology and Metabolism,
657 2021. **321**(6): p. E795-E801.
658 45. Lillegard, K., J.A. Del Castillo, and H.J. Silver, *Poorly controlled glycemia and worse*
659 *beta cell function associate with higher resting and total energy expenditure in adults*
660 *with obesity and type 2 diabetes: A doubly labeled water study.* Clinical Nutrition, 2024.
661 **43**(3): p. 729-738.
662 46. Liao, W., et al., *Persistent high glucose induced EPB41L4A-AS1 inhibits glucose uptake*
663 *via GCN5 mediating crotonylation and acetylation of histones and non-histones.* Clin
664 Transl Med, 2022. **12**(2): p. e699.
665 47. Shan, S., et al., *Marine algae-derived oligosaccharide via protein crotonylation of key*
666 *targeting for management of type 2 diabetes mellitus in the elderly.* Pharmacological
667 Research, 2024. **205**: p. 107257.
668 48. Belostotsky, R., J.J. Pitt, and Y. Frishberg, *Primary hyperoxaluria type III—a model for*
669 *studying perturbations in glyoxylate metabolism.* Journal of Molecular Medicine, 2012.
670 **90**(12): p. 1497-1504.
671 49. Schnedler, N., G. Burckhardt, and B.C. Burckhardt, *Glyoxylate is a substrate of the*
672 *sulfate-oxalate exchanger, sat-1, and increases its expression in HepG2 cells.* Journal of
673 Hepatology, 2011. **54**(3): p. 513-520.
674 50. Nikiforova, V.J., et al., *Glyoxylate, a new marker metabolite of type 2 diabetes.* J
675 Diabetes Res, 2014. **2014**: p. 685204.
676 51. Song, S., *Can the glyoxylate pathway contribute to fat-induced hepatic insulin*
677 *resistance?* Med Hypotheses, 2000. **54**(5): p. 739-47.
678 52. Padberg, I., et al., *A new metabolomic signature in type-2 diabetes mellitus and its*
679 *pathophysiology.* PLoS One, 2014. **9**(1): p. e85082.
680 53. Franklin, I.K. and C.B. Wollheim, *GABA in the endocrine pancreas: its putative role as*
681 *an islet cell paracrine-signalling molecule.* J Gen Physiol, 2004. **123**(3): p. 185-90.
682 54. Michalik, M. and M. Erecińska, *Gaba in pancreatic islets: Metabolism and function.*
683 Biochemical Pharmacology, 1992. **44**(1): p. 1-9.

684 55. Curovic, V.R., et al., *Circulating Metabolites and Lipids Are Associated to Diabetic*
685 *Retinopathy in Individuals With Type 1 Diabetes.* Diabetes, 2020. **69**(10): p. 2217-2226.
686 56. Hou, D. and Y. Yang, *Genetically predicted elevated circulating 3,4-dihydroxybutyrate*
687 *levels mediate the association between family Christensenellaceae and osteoporosis risk:*
688 *a Mendelian randomization study.* Front Endocrinol (Lausanne), 2024. **15**: p. 1388772.
689 57. Molinaro, A., et al., *Imidazole propionate is increased in diabetes and associated with*
690 *dietary patterns and altered microbial ecology.* Nature Communications, 2020. **11**(1): p.
691 5881.
692 58. Koh, A., et al., *Microbially Produced Imidazole Propionate Impairs Insulin Signaling*
693 *through mTORC1.* Cell, 2018. **175**(4): p. 947-961.e17.
694 59. Le Chatelier, E., et al., *Richness of human gut microbiome correlates with metabolic*
695 *markers.* Nature, 2013. **500**(7464): p. 541-546.
696 60. Ma, Q., et al., *Therapeutic mechanisms of mulberry leaves in type 2 diabetes based on*
697 *metabolomics.* Front Pharmacol, 2022. **13**: p. 954477.
698 61. Katsoulidis, A.P., et al., *Chemical control of structure and guest uptake by a*
699 *conformationally mobile porous material.* Nature, 2019. **565**(7738): p. 213-217.
700 62. D'Souza, S.E., M.H. Ginsberg, and E.F. Plow, *Arginyl-glycyl-aspartic acid (RGD): a cell*
701 *adhesion motif.* Trends Biochem Sci, 1991. **16**(7): p. 246-50.
702 63. Ippolito, J.A., R.S. Alexander, and D.W. Christianson, *Hydrogen bond stereochemistry in*
703 *protein structure and function.* Journal of Molecular Biology, 1990. **215**(3): p. 457-471.
704 64. American Diabetes Association Professional Practice, C., *2. Diagnosis and Classification*
705 *of Diabetes: Standards of Care in Diabetes-2025.* Diabetes Care, 2025. **48**(1 Suppl 1): p.
706 S27-S49.
707 65. Wallace, T.M., J.C. Levy, and D.R. Matthews, *Use and abuse of HOMA modeling.*
708 Diabetes Care, 2004. **27**(6): p. 1487-95.
709 66. Prystupa, K., et al., *Comprehensive validation of fasting-based and oral glucose*
710 *tolerance test-based indices of insulin secretion against gold standard measures.* BMJ
711 Open Diabetes Res Care, 2022. **10**(5).
712 67. Pacini, G., et al., *Insulin sensitivity and glucose effectiveness: minimal model analysis of*
713 *regular and insulin-modified FSIGT.* American Journal of Physiology-Endocrinology and
714 Metabolism, 1998. **274**(4): p. E592-E599.
715 68. Bergman, R.N., et al., *Quantitative estimation of insulin sensitivity.* Am J Physiol, 1979.
716 **236**(6): p. E667-77.
717 69. Pei, G., L. Chen, and W. Zhang, *WGCNA Application to Proteomic and Metabolomic*
718 *Data Analysis.* Methods Enzymol, 2017. **585**: p. 135-158.
719 70. Ritchie, M.E., et al., *limma powers differential expression analyses for RNA-sequencing*
720 *and microarray studies.* Nucleic Acids Research, 2015. **43**(7): p. e47-e47.
721 71. Law, C.W., et al., *A guide to creating design matrices for gene expression experiments.*
722 F1000Res, 2020. **9**: p. 1444.
723 72. Smyth, G.K., *Linear models and empirical bayes methods for assessing differential*
724 *expression in microarray experiments.* Stat Appl Genet Mol Biol, 2004. **3**: p. Article3.

756 **Figure 6**. Differential expression analysis. Heatmaps of all metabolites with significant group-
757 by-time interaction effects, plotted at baseline (A) and 120 minutes after an oral glucose
758 tolerance test (OGTT) (B). Interaction plots of all metabolites with significant interaction effects
759 (C). Analysis of differential metabolite abundance was conducted using linear models
760 implemented with the *limma* package (*duplicateCorrelation* was calculated and used to model
761 the random effects of the Subject_ID variable to account for the correlation between the repeated
762 measures at baseline and OGTT-120min). Metabolomic features with fold change FC>1.5,
763 P<0.05, and FDR<0.05 were considered significant.

764 **Figure 7**. Expression of serum 3S,4-dihydroxy-butyric acid, GABA, and their respective
765 correlation at baseline (A) and after the oral glucose challenge (OGTT) (B). Color-coded
766 boxplots and scatter plots: NGT: blue, PreT2D: orange, T2D: red.

767 **Figure 8**. Significant correlations (absolute /r/>0.4, P<0.05, FDR<0.1) between baseline serum
768 levels of crotonic acid and baseline serum levels of crotonylated EV cargo proteins. Color-coded
769 scatter plots: NGT: blue, PreT2D: orange, T2D: red.

Select BASELINE Modules

Select DELTA Modules

A

Overview of Enriched Metabolite Sets (Top 25)

BASELINE Magenta

Enrichment Ratio
- 6
- 8
- 10

P-value
0.15
0.10
0.05
0.00

Metabolite sets (top to bottom):
Glycine and Serine Metabolism, Citric Acid Cycle, Amino Sugar Metabolism, Transfer of Acetyl Groups into Mitochondria, Valine, Leucine and Isoleucine Degradation, Warburg Effect, Tyrosine Metabolism, Galactose Metabolism, Alanine Metabolism, Urea Cycle, Glutamate Metabolism, Inositol Metabolism, Cysteine Metabolism, Propanoate Metabolism, Glycolysis, Gluconeogenesis, Threonine and 2-Oxobutanoate Degradation, Inositol Phosphate Metabolism, Phosphatidylinositol Phosphate Metabolism, Catecholamine Biosynthesis, Starch and Sucrose Metabolism, Aspartate Metabolism, Ketone Body Metabolism, Butyrate Metabolism, Glucose-Alanine Cycle

x-axis: -log10 (p-value)

B

Overview of Enriched Metabolite Sets (Top 25)

DELTA Black

Enrichment Ratio
- 6
- 8
- 10
- 12
- 14

P-value
0.125
0.100
0.075
0.050
0.025
0.000

Metabolite sets (top to bottom):
Warburg Effect, Alanine Metabolism, Citric Acid Cycle, Glutamate Metabolism, Glycine and Serine Metabolism, Ketone Body Metabolism, Butyrate Metabolism, Transfer of Acetyl Groups into Mitochondria, Valine, Leucine and Isoleucine Degradation, Carnitine Synthesis, Tyrosine Metabolism, Ammonia Recycling, Arginine and Proline Metabolism, Cysteine Metabolism, Pentose Phosphate Pathway, Glycolysis, Gluconeogenesis, Mitochondrial Electron Transport Chain, Phytanic Acid Peroxisomal Oxidation, Catecholamine Biosynthesis, Glutathione Metabolism, Porphyrin Metabolism, Amino Sugar Metabolism, Starch and Sucrose Metabolism, Glucose-Alanine Cycle

x-axis: -log10 (p-value)

Overview of Enriched Metabolite Sets (Top 25)

A Significant interaction metabolites at Baseline

B Significant interaction metabolites at 2-hour OGTT

C Group-by-Time Interaction Features

A Baseline

B OGTT-2h